Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®)

Acta Ophthalmologica

Volumn 88, Issue 8, 2010, Pages 836-841

  Algvere, Peep V ^a   Von Wendt, Gunvor ^a   Gudmundsson, Johann ^a   Seregard, Stefan ^a   Kvanta, Anders ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

bevazicumab; central retinal vein occlusion; ETDRS visual acuity; intravitreal injections; macular oedema; optical coherence tomography

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; EYE DISCOMFORT; EYE INFECTION; EYE IRRITATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR INFLAMMATION; INTRAOCULAR PRESSURE; MALE; MICROSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FOVEA; RETINA HEMORRHAGE; RETINA MACULA EDEMA; SUBRETINAL FLUID; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78649864477     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01758.x     Document Type: Article

References (23)

1. Adamis AP, Shima DT, Tolentino M, et al. (1996): Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovscularization in a nonhuman primate. Arch Ophthalmol 114: 66-71.
2. Aiello LP, Avery RL, Arrigg PG, et al. (1994): Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
3. Berker N, &, Batman C, (2008): Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86: 245-252.
4. Boyd SR, Zachary I, Chakravarthy U, et al. (2002): Correlation of increased vascular endothelial growth factor with neovascularisation and permeabillity in ischemic central vein occlusion. Arch Ophthalmol 120: 1644-1650.
5. Central Vein Occlusion Study Group (1995): Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion. Ophthalmology 102: 1425-1433.
6. Central Vein Occlusion Study Group (1997): Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115: 486-491.
7. Costa RA, Jorge R, Calucci D, et al. (2007): Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions. IBeVO study. Retina 27: 141-149.
8. Ferrara DC, Koizumi H, Spaide RF, et al. (2007): Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 144: 864-871.
9. Fung AE, Rosenfeld PJ, Reichel E, et al. (2006): The international intravitreal bevacizumab safety survey: using the internet to assess drug worldwide. Br J Ophthalmol 90: 1344-1349.
10. Green WR, Chan CC, &, Hutchins GM, (1981): Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc LXXIX: 371-422.
11. Hsu J, Kaiser RS, Sivalingam A, et al. (2007): ntravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 27: 1013-1019.
12. Hvarfner C, &, Larsson J, (2003): Is optic nerve head swelling of prognostic value in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 241: 463-467.
13. Julien S, Heiduschka P, Hofmeister S, &, Schraermeyer U, (2008): Immunohostochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retina vein occlusion. Br J Ophthalmol 92: 1424-1428.
14. Kernt M, Neubauer AS, Kampik K, et al. (2007): Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85: 119-120.
15. Matsumoto Y, Freund KB, Peiretti E, et al. (2007): Rebound macular edema following bevacizumab (Avastin) therapy for retina venous occlusive disease. Retina 27: 426-431.
16. Mohamed Q, McIntosh RL, Saw SM, et al. (2007): Interventions for central retinal vein occlusion. An evidence-based systemic review. Ophthalmology 114: 507-519.
17. Noma H, Funatsu H, Yamasaki M, et al. (2005): Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and Interleukon-6. Am J Ophthalmol 140: 256-261.
18. Pe'er J, Folberg R, Itin A, et al. (1998): Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105: 412-414.
19. Prager F, Michels S, Kriechbaum K, et al. (2009): Intravitreal bevacizumab (Avastin®) for macular edema secondary to retinal vein occlusion-twelve-month results of a prospective clinical trial. Br J Ophthalmol. 93: 452-456.
20. Priglinger SG, Wolf AH, Kreutzer TC, et al. (2007): Intravitreal bevacizumab injections for treatment of central retinal vein occlusion. Retina 27: 1004-1012.
21. Rensch F, Jonas JB, &, Spandau UH, (2009): Early intravitreal bevacizumab for non-ischemic central vein occlusion. Acta Ophthalmol 87: 77-81.
22. Wang L, Song H, (2009): Effects of repeated injection of intravitreal triamcinolone on macular oedema in central retinal vein occlusion. Acta Ophthalmol. 87: 285-289.
23. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. (2008): Twelve-month safety of intravitereal injections of bevacizumab (Avastin): results of Pan-American Collaborative Retina Study Group. Graefes Arch Clin Exp Ophthalmol 246: 81-87.